Morgan Stanley assumed coverage of ProKidney with an Equal Weight rating and $3 price target. Recent changes to the REACT development program will likely push back the commercialization timeline, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PROK: